Standard

Dopamine transporter mutant mice in experimental neuropharmacology. / Gainetdinov, Raul R.

в: Naunyn-Schmiedeberg's Archives of Pharmacology, Том 377, № 4-6, 01.06.2008, стр. 301-313.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Gainetdinov, RR 2008, 'Dopamine transporter mutant mice in experimental neuropharmacology', Naunyn-Schmiedeberg's Archives of Pharmacology, Том. 377, № 4-6, стр. 301-313. https://doi.org/10.1007/s00210-007-0216-0

APA

Vancouver

Gainetdinov RR. Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn-Schmiedeberg's Archives of Pharmacology. 2008 Июнь 1;377(4-6):301-313. https://doi.org/10.1007/s00210-007-0216-0

Author

Gainetdinov, Raul R. / Dopamine transporter mutant mice in experimental neuropharmacology. в: Naunyn-Schmiedeberg's Archives of Pharmacology. 2008 ; Том 377, № 4-6. стр. 301-313.

BibTeX

@article{7543c985b91646bc996663056430f1bd,
title = "Dopamine transporter mutant mice in experimental neuropharmacology",
abstract = "An opportunity to perform targeted genetic manipulations in mice has provided another dimension for modern pharmacological research. Genetically modified mice have become important tools to investigate functions of previously unexplored proteins, define mechanism of action of new and known pharmacological drugs, and validate novel targets for treatment of human disorders. One of the best examples of such use of genetic models in experimental pharmacology represents investigations involving mice deficient in the gene encoding the dopamine transporter (DAT). The dopamine transporter tightly regulates the extracellular dynamics of dopamine by recapturing released neurotransmitter into the presynaptic terminals, and genetic deletion of this protein results in profound alterations in both the presynaptic homeostasis and the extracellular dynamics of dopamine. By using this model of severe dopaminergic dysregulation, significant progress has been made in defining the major target of psychotropic drugs, understanding the mechanisms of their action, unraveling novel signaling events relevant for dopaminergic transmission, and mapping neuronal pathways involved in dopamine-related behaviors. Furthermore, DAT mutant mice provided an opportunity to model in vivo conditions of extreme dopaminergic dysfunction that could be relevant for human disorders such as ADHD, schizophrenia, and Parkinson's disease and, thus, could serve as test systems for developing novel treatments for these and related disorders.",
keywords = "ADHD, DDD mice, Dopamine transporter, Knockout mice, Parkinson's disease, Schizophrenia, Serotonin",
author = "Gainetdinov, {Raul R.}",
year = "2008",
month = jun,
day = "1",
doi = "10.1007/s00210-007-0216-0",
language = "English",
volume = "377",
pages = "301--313",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer Nature",
number = "4-6",

}

RIS

TY - JOUR

T1 - Dopamine transporter mutant mice in experimental neuropharmacology

AU - Gainetdinov, Raul R.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - An opportunity to perform targeted genetic manipulations in mice has provided another dimension for modern pharmacological research. Genetically modified mice have become important tools to investigate functions of previously unexplored proteins, define mechanism of action of new and known pharmacological drugs, and validate novel targets for treatment of human disorders. One of the best examples of such use of genetic models in experimental pharmacology represents investigations involving mice deficient in the gene encoding the dopamine transporter (DAT). The dopamine transporter tightly regulates the extracellular dynamics of dopamine by recapturing released neurotransmitter into the presynaptic terminals, and genetic deletion of this protein results in profound alterations in both the presynaptic homeostasis and the extracellular dynamics of dopamine. By using this model of severe dopaminergic dysregulation, significant progress has been made in defining the major target of psychotropic drugs, understanding the mechanisms of their action, unraveling novel signaling events relevant for dopaminergic transmission, and mapping neuronal pathways involved in dopamine-related behaviors. Furthermore, DAT mutant mice provided an opportunity to model in vivo conditions of extreme dopaminergic dysfunction that could be relevant for human disorders such as ADHD, schizophrenia, and Parkinson's disease and, thus, could serve as test systems for developing novel treatments for these and related disorders.

AB - An opportunity to perform targeted genetic manipulations in mice has provided another dimension for modern pharmacological research. Genetically modified mice have become important tools to investigate functions of previously unexplored proteins, define mechanism of action of new and known pharmacological drugs, and validate novel targets for treatment of human disorders. One of the best examples of such use of genetic models in experimental pharmacology represents investigations involving mice deficient in the gene encoding the dopamine transporter (DAT). The dopamine transporter tightly regulates the extracellular dynamics of dopamine by recapturing released neurotransmitter into the presynaptic terminals, and genetic deletion of this protein results in profound alterations in both the presynaptic homeostasis and the extracellular dynamics of dopamine. By using this model of severe dopaminergic dysregulation, significant progress has been made in defining the major target of psychotropic drugs, understanding the mechanisms of their action, unraveling novel signaling events relevant for dopaminergic transmission, and mapping neuronal pathways involved in dopamine-related behaviors. Furthermore, DAT mutant mice provided an opportunity to model in vivo conditions of extreme dopaminergic dysfunction that could be relevant for human disorders such as ADHD, schizophrenia, and Parkinson's disease and, thus, could serve as test systems for developing novel treatments for these and related disorders.

KW - ADHD

KW - DDD mice

KW - Dopamine transporter

KW - Knockout mice

KW - Parkinson's disease

KW - Schizophrenia

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=45849106857&partnerID=8YFLogxK

U2 - 10.1007/s00210-007-0216-0

DO - 10.1007/s00210-007-0216-0

M3 - Article

C2 - 18057916

AN - SCOPUS:45849106857

VL - 377

SP - 301

EP - 313

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 4-6

ER -

ID: 36307844